Sep.17 -- Billionaire philanthropist Bill Gates talks about the differences between Steve Jobs and Tesla's Elon Musk. He speaks with Bloomberg's Erik Schatzker.
Sep.17 -- Billionaire philanthropist Bill Gates talks about the differences between Steve Jobs and Tesla's Elon Musk. He speaks with Bloomberg's Erik Schatzker.
Dublin, Oct. 21, 2020 (GLOBE NEWSWIRE) -- The "2020 Ambulatory Surgery Center Market Report" report has been added to ResearchAndMarkets.com's offering. The 2020 Ambulatory Surgery Center Market Report covers the industry-wide shift in surgical procedures from inpatient to outpatient setting. During first the several months of COVID-19, 100% of ASCs stopped elective surgeries, 73% stopped semi-elective surgeries, and 33% stopped non-elective surgeries. ASCs perform 41% of surgical procedures. By the mid-2020s ASCs are expected to perform 68% of orthopedic surgeriesKey Topics Covered: * Executive Summary * ASC Market Overview * Surgeries Shift To Outpatient Centers As Surgery Volumes Grow * More Surgeries Are Done At ASCs Than Any Other Setting * ASC Procedure Volumes Fall During COVID-19 * ASC Procedures Delayed During COVID-19 * ASCs Expected To Play Critical Role Post-COVID-19 * Majority Of ASCs Operate With Single Specialty * Number Of ASC Total Joint Replacement Procedures Grow * ASCs Offer Lower Cost Alternative To HOPDs * Cataract Surgery Most Performed ASC Service * Cataract Removal Leads ASC Procedures By Total Charges * Total Knee Replacement And Cardiac Procedures Added to CMS Payable List In 2020 * ASC Quality Reporting Metrics For 2020 And 2022 * 73% Of Hospital ASCs Operated As Physician Joint Ventures * Majority Of ASC Centers Are Independent * Lower Cost And Convenient Recovery Touted As Top ASC Advantages * New Technologies Are Biggest Challenge For Outpatient Care * ASC Physicians Play Key Role In Purchasing Decisions * GHX Reports $2.0 Billion In Treatment Center Sales Through Distribution In 2019 * GHX Reports Treatment Center Sales By Segment * GHX Lists Outpatient Surgery Products Sold Through Distribution For more information about this report visit https://www.researchandmarkets.com/r/kkcx8sAbout ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Accenture completed its acquisition of N3, an Atlanta-based business-to-business (B2B) sales firm.
Soothe your soul with a curated guide to the best wellness brands owned by Black womenFrom Harper's BAZAAR
Speaking today are Melissa Reiff, Chairwoman and Chief Executive Officer; and Jeff Miller, Chief Financial Officer. After Melissa and Jeff have made their formal remarks, we will open the call to questions. Before we begin, I need to remind you that certain comments made during this call regarding our plans, strategies, expectations regarding liquidity and goals, our anticipated financial performance and our plans in response to COVID-19 and the potential impact of COVID-19 on our business may constitute forward-looking statements and are made pursuant to and within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Money-saving expert Martin Lewis reveals employees who have been required to work from home since 6 April can claim tax relief for the whole year, worth £62 or £124.
The South Yorkshire region of northern England is being placed under the country’s tightest restrictions to curb the coronavirus — joining a densely populated swathe of the country where the measures have been imposed despite protests from local politicians. Dan Jarvis, mayor of the region’s biggest city of Sheffield, said Wednesday that the Tier 3 restrictions for about 1.4 million people will come into force on Saturday. “We all recognize the gravity of the situation and have taken the responsible route to ensure we save lives and livelihoods,” Jarvis said.
* Overall Survival of 13.3 months in patients, including 14 months in patients with Grade I/II tumors, suggesting clinical benefit; * Comparison: 7.2-9.8 months in similar patients with metastatic breast cancer in the third line setting without BriaCell’s treatment; * Additional overall survival data will be presented at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11. BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces the overall survival (OS) data of its lead product candidate, Bria-IMT™, in combination with Checkpoint Inhibitors in advanced breast cancer patients. Additional overall survival data from the clinical studies will be presented in a poster session on December 9 – 11 during the 2020 San Antonio Breast Cancer Symposium® (SABCS), a virtual event.Median OS of 13.3 months has been observed in the Phase I/IIa study for patients treated with Bria-IMT™ in combination with immune checkpoint inhibitors in patients with advanced breast cancer (third line or later). Further, median OS had reached 14 months in patients with Grade I/II tumors. Checkpoint inhibitors included pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.), and more recently, Incyte’s INCMGA00012 (by Incyte Corporation). This data is derived primarily from patients previously disclosed (see press release dated June 22, 2020). An OS of 7.2-9.8 months in similar patients with metastatic breast cancer in the third line setting has recently been published (Kazmi S, et al. “Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.” Breast Cancer Res Treat. 2020). The SABCS® poster will also summarize the clinical and pathological data of the Bria-IMT™ monotherapy study and Phase I/IIa clinical study of Bria-IMT™ in combination with immune checkpoint inhibitors including pembrolizumab, and more recently, Incyte’s INCMGA00012, in advanced breast cancer with grade I and grade II tumors.The SABCS® presentation will be posted on https://briacell.com/novel-technology/scientific-publications/.The details on the SABCS® poster presentation are as follows:Abstract Number: 1313 Presentation Title: Response to a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer correlates with tumor grade Session Date: December 9-11, 2020 Program Number: PS17-20 Session Title: Poster Session 17 About BriaCellBriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.For additional information on BriaCell, please visit: https://briacell.com/.About SABCS®Since its inception in 1977, San Antonio Breast Cancer Symposium (SABCS®) has grown to a program that covers the latest research on the experimental biology, etiology, prevention, diagnosis, and treatment of breast cancer and premalignant breast disease. The Symposium is attended by a large international audience of researchers, health professionals, physicians, oncologists, and those with a special interest in breast cancer from over 90 countries.To complement the clinical focus of the annual SABCS®, Baylor College of Medicine became a joint sponsor of SABCS® in 2005. Additionally, the Cancer Therapy & Research Center (CTRC) at UT Health Science Center San Antonio and American Association for Cancer Research (AACR), a prestigious scientific organization known for its basic, translational and clinical cancer research, began collaboration with SABC® in 2007. The Symposium was renamed the CTRC-AACR San Antonio Breast Cancer Symposium.For additional information on 2020 SABCS®, please visit: https://www.sabcs.org.Cautionary Note Regarding Forward-Looking InformationExcept for the statements of historical fact, this news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation (also known as "forward-looking statements") which are subject to known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company's public filings available at www.sedar.com.These forward-looking statements include, but are not limited to, BriaCell’s plans, objectives, expectations and intentions. Such forward-looking statements reflect BriaCell's current beliefs and are based on information currently available to management. Although the forward-looking statements contained in this news release are based upon what BriaCell believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Contact InformationFor further information, please contact:BriaCell Therapeutics Corp.: William V. Williams, MD President & CEO Phone: 1-888-485-6340BriaCell Therapeutics Corp.: Farrah Dean Manager, Corporate Development Email: farrah@BriaCell.com Phone: 1-888-485-6340
VERO BEACH, Florida, Oct. 21, 2020 (GLOBE NEWSWIRE) -- ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced the November 2020 cash dividend for the Company's Common Stock. November 2020 Common Stock Dividend InformationMonth Dividend Holder of Record Date Payment Date November 2020 $0.10 November 16, 2020 November 27, 2020 Certain Tax MattersARMOUR has elected to be taxed as a real estate investment trust (“REIT”) for U.S. Federal income tax purposes. In order to maintain this tax status, ARMOUR is required to timely distribute substantially all of its ordinary REIT taxable income. Dividends paid in excess of current tax earnings and profits for the year will generally not be taxable to common stockholders. Actual dividends are determined at the discretion of the Company’s board of directors, which may consider additional factors including the Company’s results of operations, cash flows, financial condition and capital requirements as well as current market conditions, expected opportunities and other relevant factors.About ARMOUR Residential REIT, Inc.ARMOUR invests primarily in fixed rate residential, adjustable rate and hybrid adjustable rate residential mortgage‑backed securities issued or guaranteed by U.S. Government-sponsored enterprises or guaranteed by the Government National Mortgage Association. ARMOUR is externally managed and advised by ARMOUR Capital Management LP, an investment advisor registered with the Securities and Exchange Commission (“SEC”).Safe HarborThis press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. The Company disclaims any obligation to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.Additional Information and Where to Find ItInvestors, security holders and other interested persons may find additional information regarding the Company at the SEC’s internet site at www.sec.gov, or the Company website at www.armourreit.com, or by directing requests to: ARMOUR Residential REIT, Inc., 3001 Ocean Drive, Suite 201, Vero Beach, Florida 32963, Attention: Investor Relations.Investor Contact:James R. Mountain Chief Financial Officer ARMOUR Residential REIT, Inc. (772) 617-4340
Regulatory progress is spurring the development of safe and effective therapies for Alzheimer’s diseaseTORONTO and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, released a white paper today that offers its perspective on aducanumab’s likelihood of regulatory approval in advance of its U.S. Food and Drug Administration Advisory Committee (AC) review on November 6. The white paper, available at www.promisneurosciences.com, chronicles aducanumab’s history, regulatory support, positive data outcomes and potential impetus for development of improved second-generation therapies. If approved, aducanumab would be the first disease-modifying treatment for Alzheimer’s disease, offering a therapeutic option for the millions of Americans living with the disease. Aducanumab was originally designed to target amyloid-beta plaque, now believed to be an ineffective drug target for AD. An accumulating body of data has shifted the drug development focus to a different species of amyloid-beta called the toxic oligomer which has since been shown to be the real culprit in driving disease progression. Aducanumab’s ability to cross-react and partially neutralize toxic oligomers results in its modest treatment benefit. By contrast, published data show that PMN310, ProMIS’ antibody candidate for Alzheimer’s disease, is highly selective for the toxic oligomer of amyloid-beta, positioning it as a second-generation drug candidate with more precise targeting capabilities and a potentially improved safety and efficacy profile.Despite aducanumab’s modest treatment benefit, the white paper argues that FDA approval is likely based on the following: 1. FDA has encouraged Biogen to submit its application, granting it Priority Review; has endorsed continued clinical use of aducanumab in an open-label study, and; has demonstrated a willingness in the past to approve drugs despite limited data in instances where the unmet medical need is significant. 2. Aducanumab’s phase 3 EMERGE trial was unequivocally positive and additional evidence for effectiveness is confirmed by results from the Phase 1b PRIME trial and subset data from the phase 3 ENGAGE trial. 3. We anticipate the Advisory Committee members will most likely conclude that aducanumab’s data demonstrate the requisite “substantial evidence of effectiveness” and acceptable safety. “Aducanumab represents a milestone treatment, and we applaud Biogen’s unrelenting commitment to its advancement,” said Dr. Elliot Goldstein, ProMIS Neurosciences’ President and CEO. “We and many others in the Alzheimer’s community look forward to the upcoming FDA Advisory Committee meeting and subsequent regulatory actions in support of addressing the unmet need for disease modifying therapies for Alzheimer’s disease.”The FDA’s Advisory Committee will be virtually convened and streamed via internet on November 6, 2020.About ProMIS Neurosciences ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. In the infectious disease setting, these DSEs represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19. ProMIS proprietary peptide antigens can also be used to create potential therapeutic antibodies, as well as serve as the basis for development of vaccines. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn. To learn more about protein misfolding diseases, listen to Episodes 11, 24, of Saving Minds, a podcast available at iTunes or Spotify.For media inquiries, please contact: Shanti Skiffington email@example.com Tel. 617 921-0808For Investor Relations please contact: Alpine Equity Advisors Nicholas Rigopulos, President firstname.lastname@example.org Tel. 617 901-0785The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Babcock & Wilcox Renewable has been awarded a contract to provide upgrades to Shetland Islands Council’s energy recovery plant in Lerwick, Scotland.
Harvest Capital Credit Corporation (NASDAQ: HCAP) announced today that it will report its financial results for the fiscal quarter ended September 30, 2020 before market open on Friday, November 6, 2020. The company will hold a conference call to discuss the results at 11:00 a.m. ET that morning.
Integrating Intelligence Across Channels, Technologies and Content Achieves Greater Precision, Efficiency and EffectivenessMORRISVILLE, N.C., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today introduced Kinetic, a modern customer engagement capability that makes fully integrated omnichannel solutions accessible to biopharmaceutical organizations. Powered by a team of data scientists, behavioral experts and channel strategists, Kinetic delivers the right message, to the right person, at the right moment to optimize performance. This advanced capability is already being deployed for biopharmaceutical companies of all sizes. Biopharmaceutical companies have long been challenged to obtain a clear, actionable and measurable view of all of their relationship-building efforts and the impact on customer behavior. Kinetic seeks to eliminate these silos and elevate performance by creating more personalized and meaningful integrated healthcare interactions, enabling customers to more effectively reach audiences.Kinetic delivers distinct advantages that only Syneos Health can, built on the foundation of the Company’s Biopharmaceutical Acceleration Model®, including integrated, end-to-end know-how; deep therapeutic knowledge; human behavior expertise; and a highly flexible, source-agnostic technology architecture called Dynamic Assembly®. This multiple option technology network is built with contemporary, aligned partners as opposed to relying solely on in-house technologies or solutions.“Accelerating therapies to market requires breaking down traditional silos and creating precise, customized and connected approaches across the product development lifecycle from clinical development through commercialization,” said Alistair Macdonald, Chief Executive Officer of Syneos Health. “With Kinetic, we seek to efficiently assess the nuances of each trial protocol or product launch and respond with flexible, right-sized tech- and data-enabled solutions to improve performance.”Kinetic is centered on Intelligence, Experience and Performance – three pillars that are mission-critical to success in today’s technology-enabled engagement landscape. The capability features advanced targeting, unified views of channel behavior, matrixed content, person-level relevant automation and performance analytics with the goal of exceeding program targets.A cornerstone of Kinetic is Digital Amplifier, a precise surround-sound digital overlay designed to amplify sales teams and existing call plans, synchronizing personal (face-to-face) engagement with smart, relevant non-personal (digital) outreach. This represents a hybrid, hyper-efficient way to amplify field relationships by targeting media to individual prescribers across digital channels with high-service follow-ups.“Kinetic employs a sophisticated, effective system for reaching HCPs that is specifically designed to enhance the impact of active sales teams. As the leading Commercial outsourcing provider, we’ve always recommended optimized solutions – during COVID-19 we’ve accelerated these efforts, advanced this capability and validated its impact,” said Michelle Keefe, President of Commercial Solutions at Syneos Health. “For example, for a product we helped launch during COVID-19, Digital Amplifier allowed us to consistently reach 80% of HCPs on the call plan when access was down industry-wide. More impressively, our program generated a double-digit lift in total prescriptions written by HCPs that were both called on by the field and received Digital Amplifier compared to those who were only called on by the field. This is one of many examples of the power of this capability.”Kinetic delivers personally relevant healthcare engagement, providing organizations of all sizes omnichannel fluency with the flexibility to access full-scale integration or point solutions. Learn more at syneoshealth.com/kinetic.About Syneos Health Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Our Company brings together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com.Syneos Health Investor Relations Contact: Syneos Health Press/Media Contact: Ronnie Speight Danielle DeForge Senior Vice President, Investor Relations Vice President, External Communications +1 919 745 2745 +1 202 210 5992 email@example.com firstname.lastname@example.org
Radian Group Inc. (NYSE: RDN) today announced that it will hold a conference call on Thursday, November 5, 2020, at 1:00 p.m. Eastern time to discuss the company’s third quarter 2020 results, which will be announced after the market closes on Wednesday, November 4, 2020.
Company Expands Reseller Network into Middle EastVANCOUVER, BC and ERIE, Pa., Oct.
LA JOLLA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Ms. Carolyn Beaver to its Board of Directors and as Chair of its Audit Committee. Carolyn Beaver, CPA (inactive), has served as a director and member of the audit committee of MaxLinear, Inc., a leading provider of radio frequency, analog, digital and mixed-signal integrated circuits, since December 2018, and served as a director of Organovo Holdings, Inc., a biotechnology company, from February 2019 to September 2020. She chaired the audit committee of Organovo and was a member of its nominating and corporate governance committee from September 2019 to September 2020. She previously held several positions at Sequenom Inc., a life sciences testing company, including Chief Financial Officer and Senior Vice President from March 2015 to October 2016, Chief Financial Officer from June 2014 to March 2015, and Vice President and Chief Accounting Officer from June 2012 to June 2014. Ms. Beaver was previously Corporate Vice President and Controller of Beckman Coulter, Inc., a biomedical laboratory instrument and test company, from August 2005 until June 2012, and was named Chief Accounting Officer in October 2005, a position she held until July 2011, following the acquisition of Beckman Coulter, Inc. by Danaher Corporation. She also served as interim Chief Financial Officer of Beckman Coulter from July 2006 through October 2006. Ms. Beaver was a director of Commerce National Bank, Newport Beach, California, chair of its audit committee and a member of its asset/liability committee from 2005 until the bank was acquired in 2013. Ms. Beaver served as an audit partner with KPMG LLP from 1987 to 2002. She is currently on the board of directors of Working Wardrobes, Inc. and is chairman of the board of Changing Strides, both non-profit organizations. Ms. Beaver received a Bachelor of Science degree in Business Administration from California State Polytechnic University, Pomona.“We are extremely pleased and fortunate to add an individual with such strong finance and accounting expertise to MediciNova’s Board of Directors and Audit Committee,” said Yuichi Iwaki, M.D., Ph.D., MediciNova’s President and Chief Executive Officer. “We believe Ms. Beaver will be a great asset to the Company and its shareholders.”About MediciNovaMediciNova, Inc. is a publicly traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on BC-PIV SARS-COV-2 vaccine for COVID-19, MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative cervical myelopathy (DCM), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin). For more information on MediciNova, Inc., please visit www.medicinova.com.Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of BC-PIV SARS-COV-2 vaccine, MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, the risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.INVESTOR CONTACT: Geoff O’Brien Vice President MediciNova, Inc. email@example.com
QuintessenceLabs introduces new quantum entropy management solution, qStream Plus Appliance, helping solve fundamental cybersecurity challenges.
Beazer Homes (NYSE: BZH) (www.beazer.com) has scheduled the release of its financial results for the quarter ended September 30, 2020 on Thursday, November 12, 2020 after the close of the market. Management will host a conference call on the same day at 5:00 PM ET to discuss the results.
BiomX Inc. (NYSE American : PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today presented preclinical data from its phage panel for the treatment of inflammatory bowel disease at the Infectious Disease Society of America (IDSA) Infectious Disease Week (IDWeek) 2020 conference. The poster presentation details a phage therapy panel, comprised of phage directed against Klebsiella pneumoniae, showing a broad target host range and the potential to address carbapenem-resistant and extended spectrum beta-lactamase (ESBL)-producing bacteria.
NICE (Nasdaq: NICE) today announced that Midland States Bank, a wholly-owned subsidiary of Midland States Bancorp, Inc. (Nasdaq: MSBI), has selected NICE Satmetrix to unify its growth strategies, culture, and operations around its mission to continue a customer-centric culture. Having grown rapidly through acquisitions, while representing a diversified portfolio of banking services and financial products, Midland supports a wide variety of customer segments across locations, product and service touchpoints. Company leadership quickly recognized that in order to build a visibly unified customer-centric culture, they needed a holistic Voice of the Customer (VoC) solution.
The San Francisco-based company, which had 129 Gap brand stores in Europe at the end of July, said late on Tuesday options being explored include the possible closure of outlets in the United Kingdom, France, Ireland and Italy by mid-2021. The move comes as Gap struggles with out-of-fashion styles, which has pushed shoppers towards apparel brands like Zara and H&M. The coronavirus crisis has compounded troubles by stifling sales at brick-and-mortar sales across the globe. The company also said it was reviewing its warehouse and distribution model and its Gap and Banana Republic-owned e-commerce operations in Europe.